Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate

Probody therapeutics (Pb-Txs) are conditionally activated antibody–drug conjugates (ADCs) designed to remain inactive until proteolytically activated in the tumor microenvironment, enabling safer targeting of antigens expressed in both tumor and normal tissue. Previous attempts to target CD71, a hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Shweta, Serwer, Laura, DuPage, Amy, Elkins, Kristi, Chauhan, Niharika, Ravn, Matthew, Buchanan, Fritz, Wang, Leyu, Krimm, Michael, Wong, Ken, Sagert, Jason, Tipton, Kimberly, Moore, Stephen J., Huang, Yuanhui, Jang, Andrew, Ureno, Eric, Miller, Adam, Patrick, Sarah, Duvur, Shanti, Liu, Shouchun, Vasiljeva, Olga, Li, Yingchun, Henriques, Tracy, Badagnani, Ilaria, Jeffries, Shawn, Schleyer, Siew, Leanna, Rob, Krebber, Claus, Viswanathan, Sridhar, Desnoyers, Luc, Terrett, Jonathan, Belvin, Marcia, Morgan-Lappe, Susan, Kavanaugh, W. Michael, Richardson, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662867/
https://www.ncbi.nlm.nih.gov/pubmed/35666803
http://dx.doi.org/10.1158/1535-7163.MCT-21-0193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662867/
https://www.ncbi.nlm.nih.gov/pubmed/35666803
http://dx.doi.org/10.1158/1535-7163.MCT-21-0193

Ejemplares similares